Categories: BrainDiagnosticsNews

Nexstim Plc’s Financial Information in 2023

Company Announcement, Helsinki, 23 December 2022 at 1 PM (EET)

Nexstim Plc’s Financial Information in 2023

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that it will publish the following financial information in 2023:

The 2022 Financial Statements Release and Half-Yearly Report July−December 2022 (H2) on Monday, February 27, 2023. Half-Yearly Report January-June 2023 (H1) on Friday, August 11, 2023.

Nexstim’s Annual Report 2022 will be published and available on the Company’s website on Monday, March 6, 2023.

The Annual General Meeting is tentatively scheduled to be held on Friday March 31, 2023 at 10:00 am.

NEXSTIM PLC        

Mikko Karvinen, CEO

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

The Company’s Certified Advisor is Erik Penser Bank.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com

Attachment

Staff

Recent Posts

Attune to Support Poppy Health’s $39M ARPA-H BREATHE Project in the U.S. Schools

VIENNA, Va., Dec. 19, 2025 /PRNewswire/ -- Attune announced today that the company will play…

3 hours ago

Feel30 Launches Austin-Based Telehealth Platform for Evidence-Proven TRT & Integrated At-Home Phlebotomy Services

AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ -- Feel30 , a telehealth platform specializing in testosterone…

3 hours ago

LISA LING JOINS TENDERCARE AS CHIEF CAREGIVER ADVOCATE & ADVISOR

– Will help address the difficult realities sandwich generation caregivers face with family caregiving –NEW…

3 hours ago

TENDERCARE LAUNCHING NATIONAL FAMILY CAREGIVING INFRASTRUCTURE, PARTNERING WITH THE AGING LIFE CARE ASSOCIATION® AND SUPPORTING THE CMS GUIDE MODEL PROGRAM

tendercare partnering with ALCA to raise national caregiving and eldercare industry standards;Selected as CMS GUIDE…

3 hours ago

HCAP Partners Announces Investment in Puzzle Healthcare

Investment to accelerate the growth of a post-acute care platform focused on reducing hospital readmissions…

3 hours ago

The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute

IRVING, Texas, Dec. 19, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation…

3 hours ago